Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.56 |
| ▸ | LCK | P06239 | 5/20 | 0.56 |
| ▸ | TEK | Q02763 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | BTK | Q06187 | 10/20 | 0.53 |
| ▸ | ABL1 | P00519 | 3/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | YES1 | P07947 | 2/20 | 0.50 |
| ▸ | LYN | P07948 | 2/20 | 0.50 |
| ▸ | HCK | P08631 | 2/20 | 0.50 |
| ▸ | FGR | P09769 | 2/20 | 0.50 |
| ▸ | TXK | P42681 | 2/20 | 0.50 |
| ▸ | BLK | P51451 | 2/20 | 0.50 |
| ▸ | BMX | P51813 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020018 | 0.95 | SRC (0.54) | SRCLCKTEKKDRBTK | |
| SCHEMBL22418481 | 0.90 | BTK (0.55) | SRCLCKTEKKDRBTK | |
| SCHEMBL25911581 | 0.84 | BTK (0.52) | SRCLCKTEKBTKABL1 | |
| SCHEMBL20351778 | 0.82 | SRC (0.51) | SRCLCKTEKKDRBTK | |
| SCHEMBL3662271 | 0.82 | SRC (0.64) | SRCLCKTEKKDRBTK | |
| SCHEMBL20351579 | 0.81 | BTK (0.54) | SRCLCKTEKBTKABL1 | |
| SCHEMBL20182212 | 0.81 | SRC (0.49) | SRCLCKTEKKDRBTK | |
| SCHEMBL13020349 | 0.81 | SRC (0.69) | SRCLCKTEKKDRBTK | |
| SCHEMBL13020097 | 0.79 | SRC (0.57) | SRCLCKTEKKDRBTK | |
| SCHEMBL13020112 | 0.79 | SRC (0.58) | SRCLCKTEKKDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SRC 1332/4885LCK 1980/4885TEK 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.